HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need.

AbstractOBJECTIVE:
Several controlled trials have demonstrated the rapid effects of intravenous ketamine. As a result, the use of this off-label treatment has grown exponentially in recent years. This use is expected to continue to grow after the approval by the US Food and Drug Administration of intranasal esketamine for treatment-resistant depression-a decision that firmly establishes N-methyl-d-aspartate (NMDA)-receptor antagonism as a valid antidepressant mechanism of action in the public view. The limitation, however, of intravenous ketamine administration is that much less is known about how to maintain initial treatment gains. Thus, although intravenous ketamine has proved to be a rapid-acting antidepressant, maintaining its early therapeutic gains in an efficient manner has emerged as a major unmet need in the field.
DATA SOURCES:
PubMed/MEDLINE was searched from inception to March 1, 2019, using the following terms: ketamine, randomized, depression, and placebo. There were no language or date restrictions.
STUDY SELECTION:
The search was limited to randomized, placebo-controlled trials to maintain initial treatment gains of intravenous ketamine for major depressive disorder. A total of 115 manuscripts were identified, and 110 were excluded because they did not describe randomized, double-blind clinical trials.
DATA EXTRACTION:
The remaining 5 articles were reviewed.
RESULTS:
Three negative studies involving 2 oral agents (lithium and riluzole), a small negative study involving repeated ketamine infusions, and a positive yet insufficiently controlled larger study supporting infusions 2 or 3 times weekly were published.
CONCLUSIONS:
This evidence base is insufficient to inform clinical practice. Fortunately, a wide variety of molecular targets exist for this indication. Psychotherapy and exercise may also play a beneficial role. More studies are urgently needed to establish how best to maintain rapid symptom improvement seen with ketamine infusions.
AuthorsGeorge I Papakostas
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 81 Issue 2 (02 04 2020) ISSN: 1555-2101 [Electronic] United States
PMID32023369 (Publication Type: Journal Article, Systematic Review)
Copyright© Copyright 2020 Physicians Postgraduate Press, Inc.
Chemical References
  • Antidepressive Agents
  • Ketamine
Topics
  • Antidepressive Agents (administration & dosage)
  • Depressive Disorder, Major (drug therapy)
  • Humans
  • Ketamine (administration & dosage)
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: